Visual outcome after intravitreal ranibizumab for wet age-related macular degeneration: A comparison between best-corrected visual acuity and Microperimetry

Retina

Volumn 30, Issue 3, 2010, Pages 436-442

  Squirrell, David M ^a   Mawer, Nick P ^a   Mody, Christopher H ^a   Brand, Christopher S ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Age related macular degeneration; Microperimetry; Visual outcomes

Indexed keywords

RANIBIZUMAB;

ARTICLE; BEST CORRECTED VISUAL ACUITY; CENTRAL RETINAL SENSITIVITY; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; HUMAN; PERIMETRY; RETINA MACULA AGE RELATED DEGENERATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL ACUITY; VISUAL SYSTEM FUNCTION;

ANTIBODIES, MONOCLONAL; HUMANS; INJECTIONS; PERIMETRY; RETINA; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL FIELDS; VITREOUS BODY; WET MACULAR DEGENERATION;

EID: 77949411169     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181bd2f29     Document Type: Article

References (24)

1. Rosenfeld PJ, Brown DM, Heier JS, et al., Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
2. Brown DM, Kaiser PK, Michels M, et al., Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444.
3. Fung AE, Lalwani GA, Rosenfeld PJ, et al., An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age related macular degeneration. Am J Ophthalmol 2007;143:566-583.
4. McClure ME, Hart PM, Jackson AJ, Stevenson MR, Chakravarthy U. Macular degeneration: do conventional measurements of impaired visual function equate with visual disability? Br J Ophthalmol 2000;84:244-250.
5. West SK, Munoz B, Rubin GS, et al., Function and impairment in a population-based study of older adults. The SEE project. Invest Ophthalmol Vis Sci 1997;38:72-82.
6. Mangione CM, Gutierrez PR, Lowe G, Orav EJ, Seddon JM. Influence of age-related maculopathy on visual functioning and health-related quality of life. Am J Ophthalmol 1999;128: 45-53.
7. Scott IU, Schein OD, West S, Bandeen-Roche K, Enger C, Folstein MF. Functional status and quality of life measurements among ophthalmic patients. Arch Ophthalmol 1994; 112:329-335.
8. Hazel CA, Petre KL, Armstrong RA, Benson MT, Frost NA. Visual function and subjective quality of life compared in subjects with acquired macular disease. Invest Ophthalmol Vis Sci 2000;41:1309-1314.
9. Midena E, Degli Angeli C, Blarzino MC, Valenti M, Segato T. Macular function impairment in eyes with early age-related macular degeneration. Invest Ophthalmol Vis Sci 1997;38: 469-477.
10. Springer C, Bültmann S, Völcker HE, Rohrschneider K. Fundus perimetry with the Micro Perimeter 1 in normal individuals: comparison with conventional threshold perimetry. Ophthalmology 2005;112:848-854.
11. Rohrschneider K, Springer C, Bültmann S, Völcker HE. Microperimetry- comparison between the micro perimeter 1 and scanning laser ophthalmoscope-fundus perimetry. Am J Ophthalmol 2005;139:125-134.
12. Bland JM, Altman DG. Measuring agreement in method comparison studies. Stat Methods Med Res 1999;8:135-160.
13. Okada K, Yamamoto S, Mizunoya S, Hoshino A, Arai M, Takatsuna Y. Correlation of retinal sensitivity measured with fundus-related microperimetry to visual acuity and retinal thickness in eyes with diabetic macular edema. Eye 2006;20: 805-809.
14. Ozdemir H, Karacorlu SA, Senturk F, Karacorlu M, Uysal O. Assessment of macular function by microperimetry in unilateral resolved central serous chorioretinopathy. Eye 2008;22: 204-208.
15. Richter-Mueksch S, Vécsei-Marlovits PV, Sacu SG, Kiss CG, Weingessel B, Schmidt-Erfurth U. Functional macular mapping in patients with vitreomacular pathologic features before and after surgery. Am J Ophthalmol 2007;144:23-31.
16. Yodoi Y, Tsujikawa A, Kamed T, et al., Central retinal sensitivity measured with the micro perimeter 1 after photodynamic therapy for polypoidal choroidal vasculopathy. Am J Opthalmol 2007;143:984-994.
17. Carpineto P, Ciancaglini M, Di Antonio L, Gavalas C, Mastropasqua L. Fundus microperimetry patterns of fixation in type 2 diabetic patients with diffuse macular edema. Retina 2007;27:21-29.
18. Schmitz-Valckenberg S, Fan K, Nugent A, et al., Correlation of functional impairment and morphological alterations in patients with group 2A idiopathic juxtafoveal retinal telangiectasia. Arch Ophthalmol 2008;126:330-335.
19. Midena E, Vujosevic S, Convento E, Manfre' A, Cavarzeran F, Pilotto E. Microperimetry and fundus autofluorescence in patients with early age-related macular degeneration. Br J Opthalmol 2007;91:1499-1503.
20. Frisen L, Frisen M. Micropsia and visual acuity in macular edema. A study of the neuro-retinal basis of visual acuity. Albrecht Von Graefes Arch Klin Exp Ophthalmol 1979;2: 69-77.
21. Fletcher DC, Schuchard RA. Visual function in patients with choroidal neovascularization resulting from age-related macular degeneration: the importance of looking beyond visual acuity. Optom Vis Sci 2006;83:178-189.
22. Parisi V, Perillo L, Tedeschi M, et al., Macular function in eyes with early age-related macular degeneration with or without contralateral late age-related macular degeneration. Retina 2007;27:879-890.
23. Bansback N, Czoski-Murray C, Carlton J, et al., Determinants of health related quality of life and health state utility in patients with age related macular degeneration: the association of contrast sensitivity and visual acuity. Qual Life Res 2007; 16:533-543.
24. Brown MM, Brown GC, Brown HC, Peet J. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration. Ophthalmology 2008; 115:1039-1045.